Mainz Biomed, a molecular genetics diagnostic company specializing in the early detection of cancer, is launching a series of events to spread awareness of the importance of early detection of colorectal cancer in Germany. Not only is Mainz Biomed engaging medical professionals, but also patients, their families, caregivers, and the general public in this important initiative. Early detection of CRC is a critical part of the fight against this disease, and Mainz Biomed is dedicated to making sure everyone is informed of the risks and the potential for successful treatment.
Colorectal cancer (CRC) is one of the most common and second most lethal forms of cancer, with approximately 73,000 new cases diagnosed every year in Germany alone. Fortunately, the 5-year-survival rate is over 90% when identified in its early stages. To support the efforts of patient organizations and the local cancer community during Colorectal Cancer Awareness Month, Mainz Biomed, based in Mainz, Germany, has organized educational events to emphasize the importance of early diagnosis and the potential of a user-friendly, non-invasive, at-home CRC test kit to save lives.
Support of Gastro Update 2023 in Mainz and Berlin as Sponsor
This year, Mainz Biomed is proud to sponsor Gastro Update, a two-day practical training series for healthcare professionals led by renowned German gastroenterology experts. With a presence at both the Mainz and Berlin events, Mainz Biomed will have an opportunity to showcase their booth and participate in the subsequent stakeholder dinner. This is an excellent opportunity to further promote their commitment to excellence in healthcare.
Patient Education Day in Mainz City Center
Mainz Biomed is excited to present a unique educational event in Mainz, Germany for patients, their families, caregivers, and advocates, as well as the general public. Located conveniently in front of the National Theater, the Company will have a pavilion and several info tables to answer any questions the public may have about early CRC detection. Physicians, scientists and experts will be on hand to provide accurate information and guidance. Don’t miss out on this amazing opportunity!
ColoAlert, Mainz Biomed’s innovative, non-invasive colorectal cancer screening test, is revolutionizing early detection. The CE-IVDR marked product looks for more than just blood – analyzing tumor DNA to detect both bleeding and non-bleeding tumors. ColoAlert boasts significantly higher sensitivity and specificity than fecal occult blood tests (FOBT), with the potential to detect more cases of colorectal cancer in its early stages. Currently available in a selection of countries in the EU and UAE, Mainz Biomed is preparing to launch in the United States with a scalable distribution model through regional and national laboratory service providers. ColoAlert is changing the way we screen for colorectal cancer, one step at a time.
About Colorectal Cancer
Colorectal cancer is a devastating and deadly disease, yet it is also one of the most preventable forms of cancer with early detection. In 2021, the American Cancer Society estimated 149,500 new cases in the US, and sadly, 52,980 resulting in death. However, the recent FDA decision to recommend a stool DNA test called ColoAlert for all those over the age of 45 in the US, provides hope that the mortality rate of this disease can drastically decrease. If this recommendation is followed, the US market opportunity for CRC screening will grow to an estimated $3.7 billion per year, and with the number of Americans aged 50+ expected to rise to 157 million within 10 years, this could mean a new dawn in the fight against colorectal cancer.
About Mainz Biomed NV
Mainz Biomed is revolutionizing molecular genetic diagnostics with its market-ready solutions for life-threatening conditions. Its flagship product, ColoAlert, is a non-invasive, easy-to-use, and highly accurate diagnostic test for colorectal cancer, currently available in Europe and the United Arab Emirates. Mainz Biomed is also in the process of obtaining FDA approval in the US, with a pivotal clinical trial currently underway. In addition, the Company is developing PancAlert, a screening test for early-stage pancreatic cancer, which uses real-time PCR multiplex detection of molecular-genetic biomarkers in stool samples.